EHA HIGHLIGHTS 2024 - LYMPHOMA ROUNDTABLE DISCUSSION: MOSUNETUZUMAB DEMONSTRATES CLINICALLY MEANINGFUL OUTCOMES IN HIGH-RISK PATIENTS WITH HEAVILY PRE-TREATED R/R FL